Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) Research & Development (2016 - 2026)

Apyx Medical filings provide 15 years of Research & Development readings, the most recent being $971000.0 for Q4 2025.

  • On a quarterly basis, Research & Development fell 13.07% to $971000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.4 million, a 33.07% decrease, with the full-year FY2025 number at $3.4 million, down 33.07% from a year prior.
  • Research & Development hit $971000.0 in Q4 2025 for Apyx Medical, up from $801000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.4 million in Q2 2024 to a low of $801000.0 in Q3 2025.
  • Median Research & Development over the past 5 years was $1.1 million (2024), compared with a mean of $1.1 million.
  • Biggest five-year swings in Research & Development: surged 32.8% in 2023 and later crashed 42.45% in 2025.
  • Apyx Medical's Research & Development stood at $947000.0 in 2021, then surged by 32.52% to $1.3 million in 2022, then increased by 11.79% to $1.4 million in 2023, then fell by 20.38% to $1.1 million in 2024, then decreased by 13.07% to $971000.0 in 2025.
  • The last three reported values for Research & Development were $971000.0 (Q4 2025), $801000.0 (Q3 2025), and $824000.0 (Q2 2025) per Business Quant data.